Purpose of Review Hospital-acquired and ventilator-associated pneumonia (VAP) are frequent causes of infection among critically ill patients. VAP is the most common hospital-acquired bacterial infection among mechanically ventilated patients. Unfortunately, many of the nosocomial Gram-negative bacteria that cause VAP are increasingly difficult to treat. Additionally, the evolution and dissemination of multi-and pan-drug resistant strains leave clinicians with few treatment options. VAP patients represent a dynamic population at risk for antibiotic failure and under-dosing due to altered antibiotic pharmacokinetic parameters. Since few antibiotic agents have been approved within the last 15 years, and no new agents specifically targeting VAP have been approved to date, it is anticipated that this problem will worsen. Given the public health crisis posed by resistant Gramnegative bacteria, it is essential to establish a firm understanding of the current epidemiology of VAP, the changing trends in Gram-negative resistance in VAP, and the current issues in drug development for Gram-negative bacteria that cause VAP. Recent Findings Rapid identification technologies and phenotypic methods, new therapeutic strategies, and novel treatment paradigms have evolved in an attempt to improve treatment outcomes for VAP; however, clinical data supporting alternative treatment strategies and adjunctive therapies remain sparse. Importantly, new classes of antimicrobials, novel virulence factor inhibitors, and beta-lactam/beta-lactamase inhibitor combinations are currently in development. Conscientious stewardship of new and emerging therapeutic agents will be needed to ensure they remain effective well into the future.
Diagnostic Testing
Improved definitions paired with cutting-edge diagnostics may improve the accuracy of VAP identification. Standard culture-based testing requires specimen inoculation and growth in media, with identification and susceptibility results occurring days later. Molecular methods (i.e., rapid diagnostics) can identify Gram-negative species and detect resistance minutes to hours after specimen collection. The revolution in rapid diagnostics means that near real-time pathogen and resistance identification is possible.
Genotypic Methods
Genotypic tests, like automated real-time multiplex polymerase chain reaction (PCR) and microarray platforms, are examples of emerging diagnostic methods [17, 18] . Curetis Unyvero (Curetis AG) is a multiplex PCR hybridization system designed to identify pneumonia pathogens and resistance genes in respiratory samples [19] . A similar panel is under development for the Biofire platform. Verigene is a nanoparticle-based amplification method for identifying Gram-negative species and resistance genes, but this panel is only Food and Drug Administration (FDA)-approved for positive blood cultures identified using conventional growth detection methods [20] . Ribosomal amplification (e.g., 16S ribosomal RNA gene PCR) has also been evaluated in suspected VAP cases [21, 22] .
Phenotypic Methods
Rapid phenotypic methods provide susceptibility or resistance classification and may complement rapid identification methods. The Carba NP test (Biomerieux) directly detects carbapenem hydrolysis and can identify the presence of specific carbapenemases irrespective of species [23] . Automated systems, like the Accelerate Pheno system (Accelerate Diagnostics), provide identification and susceptibility data 1-2 days faster than traditional methods [24] .
Other Emerging Methods
Emerging technologies are able to identify Gram-negative bacteria directly from clinical specimens. T2Bacteria (T2Biosystems) utilizes magnetic resonance to identify pathogens directly from blood, but this panel has not been FDA cleared [25] . Deep sequencing technologies have also recently been applied to clinical specimens.
Epidemiology of Gram-Negative VAP Pathogens
Gram-negative VAP pathogens are increasingly antibiotic resistant [4, 26] . National and international surveillance databases (e.g., NHSN, INFORM, SENTRY) document the dissemination of Gram-negative resistance [26] [27] [28] . For example, up to 40% of select Gram-negatives in the USA exhibit multi-drug resistance (MDR) [5] , suggesting that broad empiric therapy may be required. Recent trials also provide Gram-negative recovery and susceptibility rates. In the following section, we review trends from surveillance databases and clinical trials.
USA, as confirmed in multiple studies (Table 1) [26] [27] [28] 30] . European clinical studies also support the prominent role of P. aeruginosa in VAP (14-19% of cases) [31, 32] .
Acinetobacter baumannii
A. baumannii ranks among the top five VAP pathogens worldwide. NHSN surveillance identified A. baumannii as the fifth most common VAP pathogen in the USA and Europe, accounting for 6.1 to 7.5% of VAP cases (Table 1) [26, 27] . However, only 2.7 and 3.3% of US VAP isolates were A. baumannii in the SENTRY and INFORM databases, respectively [28, 30] . The prevalence of A. baumannii within Asian countries was slightly higher than US and European rates [33, 34] .
Enterobacteriaceae
Members of the Enterobacteriaceae genus have also been frequently recovered in VAP; four of the top ten Gramnegative VAP pathogens are Enterobacteriaceae [27] . K. pneumoniae and Enterobacter spp. were identified in 10.2 and 8.3% of VAP cases by NHSN surveillance [27] and contributed 10.0 and 7.7% of VAP cases, respectively, within SENTRY [30] . INFORM found slightly higher rates of K. pneumoniae and Enterobacter spp. among Gram-negative VAP cases (Table 1) [28] . E. coli and Serratia spp. are also among the top ten VAP pathogens [26, 28, 30] . Within the European and Mediterranean regions, Enterobacteriaceae were also common [26] and increasing in frequency [35] . E. coli was the most common European pathogen. Klebsiella spp. were responsible for a similar proportion of infections in Europe and the USA (11.6 vs. 9.7%) ( Table 1) .
Recent Trends in Gram-Negative Resistance
Gram-negative resistance has become a global crisis. Among Gram-negative VAP pathogens, multidrug resistance and resistance to last-line agents (e.g., colistin) is alarmingly common. Resistance among P. aeruginosa and A. baumannii has become the norm, while carbapenem resistance among Enterobacteriaceae has emerged as an imminent threat to global health [4, 36] . In the following section, we review Gram-negative VAP pathogen resistance trends using Clinical and Laboratory Standards Institute definitions (2010-present).
P. aeruginosa Resistance
P. aeruginosa has the capacity to develop resistance to all VAP antibiotics. Carbapenem resistance has been documented in 16.1-28.4% of US nosocomial pneumonia isolates [26] [27] [28] 30] . Among VAP isolates, P. aeruginosa resistance to antipseudomonal penicillins (e.g., piperacillin-tazobactam, 15.6-19.1%) and anti-pseudomonal cephalosporins (e.g., ceftazidime or cefepime, 9.5-29.4%) is increasingly common [26] [27] [28] 30] . The aminoglycosides tobramycin and amikacin appear to retain good individual activity against P. aeruginosa in some studies (> 90% susceptible) [26, 28] . However, resistance to ≥ 1 aminoglycoside (e.g., amikacin or gentamicin or 
Enterobacteriaceae Resistance
Resistance among Enterobacteriaceae is particularly concerning and often varies by genera. In the USA, cefepime or ceftazidime resistance varies widely (2.7-30%) [26, 27] . Carbapenem resistance in E. coli and Enterobacter spp. remains relatively low (0.5-2.2% and 1-3.2%, respectively) [26] [27] [28] . Klebsiella spp. have demonstrably higher carbapenem-resistance rates (6.9-11.5%) [26] [27] [28] . European and Mediterranean Enterobacteriaceae were more likely to exhibit MDR and to carry genes encoding extendedspectrum beta-lactamases (ESBLs) [26] . Similar to the US, carbapenem resistance among Klebsiella spp. was common [26] . Carbapenem-resistant Enterobacteriaceae (CRE) were found in 58 centers in 18 European countries, comprising 2% of all Enterobacteriaceae; however, large inter-country variability exists [30] . Cases of colistinresistant mcr-1-carrying Enterobacteriaceae infections have been documented in the USA, Europe, and Asia [38] [39] [40] . The global dissemination of CRE and mcr-1-carrying isolates has significantly impacted the management of VAP patients, leaving clinicians with few or no safe and effective treatments.
Contemporary Treatment Strategies for Gram-Negative VAP
While new therapeutic agents and novel treatment approaches are currently being investigated, clinicians caring for patients with Gram-negative VAP are caught between two opposing forces: increasing resistance on one hand and a dwindling antibiotic armamentarium on the other. In the following section, we describe new antibiotics, new uses of older antibiotics, and novel strategies for Gram-negative VAP pathogens.
Agents for the Treatment of VAP Caused by MDR Gram-Negative Bacteria
The increasing frequency with which MDR Gram-negative bacteria cause VAP has forced clinicians and pharmaceutical companies to become more creative. Old antibiotics have been recycled, established antibiotics have been used in new ways, new antibiotics have been developed, and entirely novel therapeutic strategies are being investigated (Table 2) .
Renaissance Antibiotics
Antimicrobial resistance has become so pervasive and extreme that formerly discarded antibiotics are being recycled in attempts to find agents that retain activity against MDR bacteria. Some of these "renaissance antibiotics" now play an important role in clinical practice.
Fosfomycin Fosfomycin is a derivative of phosphonic acid that blocks an early stage in the synthesis of peptidoglycan, a component of the bacterial cell wall [41] . First discovered in 1969 [42] , fosfomycin has recently received renewed interest for MDR Gram-negative bacteria. Approximately three fourths of carbapenem-resistant K. pneumoniae isolates are susceptible to fosfomycin [43] . However, fosfomycin monotherapy is less active against P. aeruginosa and A. baumannii, with resistance emerging rapidly [44] . Although not currently available in the USA, intravenous fosfomycin penetrates the lung well, and limited data suggest it may be efficacious in this setting [45] .
Polymyxins First used in the 1950s, systemic polymyxins [B and E (i.e., colistin)] were abandoned by the early 1980s due to toxicity and availability of safer alternatives. In recent years, they have re-emerged for the treatment of MDR Gram-negative bacteria, including P. aeruginosa, Acinetobacter spp., E. coli, and Klebsiella spp. However polymyxins lack activity against some other Gram-negatives, such as Proteus and Serratia spp. Susceptibility notwithstanding, polymyxins suffer from two disadvantages. High-dose systemic polymyxin regimens that are necessary for serious infections like VAP have been associated with renal toxicity rates of 20% or more [46] , and cure rates with monotherapy are low [47] . Thus, current VAP guidelines suggest avoiding systemic polymyxins when alternatives exist [9] .
Minocycline Minocycline, an FDA-approved semisynthetic tetracycline derivative first developed in the 1960s [48] , has only recently been used for MDR Gram-negative VAP [49] . Like tigecycline, minocycline has Gram-negative activity [50] but yields higher blood levels than tigecycline [51] . Minocycline is active against some Acinetobacter and Stenotrophomonas spp. and some Enterobacteriaceae but not Serratia spp., Proteus spp., or P. aeruginosa [50] . Minocycline has garnered interest for MDR A. baumannii VAP, with a number of clinical responses reported across 23 cases [49] . Though controlled VAP trials are lacking, minocycline exhibits good lung penetration [measured by the epithelial lining fluid to serum (ELF/serum) AUC ratiõ 2.5] and A. baumannii killing in a mouse model [52] .
New Antibiotics
Approved Antibiotics
Tigecycline Tigecycline, a glycylcycline antibiotic approved by the FDA in 2005, has broad Gram-negative activity including some CRE [30] but not P. aeruginosa or Proteus mirabilis.
In a randomized controlled trial of 945 people with HAP/VAP, tigecycline was associated with lower response rates than imipenem [53] . Tigecycline was also associated with excess mortality in several studies [54] [55] [56] , driven primarily by patients with nosocomial pneumonia. For these reasons, tigecycline should primarily be used as a component of combination therapy [9] .
Doripenem Doripenem, a carbapenem approved by the FDA in 2007, initially showed promise for treatment of patients with Gram-negative VAP [57] . In vitro testing showed slightly lower MICs against P. aeruginosa compared to other carbapenems [58] . However, a subsequent study of 274 patients with Gram-negative VAP randomly assigned to receive a 7-day course of doripenem or a 10-day course of imipenem-cilastatin was stopped prematurely due to a lower cure rate (45.6 vs. 56.8%; 95% CI, − 26.3 to 3.8%) and higher all-cause 28-day mortality (21.5 vs. 14.8%; 95% CI, − 5.0 to 18.5) in the doripenem treatment arm [59] . As a result, current VAP guidelines do not recommend the use of doripenem [9] .
Ceftazidime-Avibactam Unlike other approved beta-lactamase inhibitors, avibactam is not a beta-lactam but does bind betalactamases. Ceftazidime-avibactam has enhanced activity against Enterobacteriaceae (including ceftazidime-resistant strains) and P. aeruginosa. Arguably, the most useful aspect of this antibiotic is its ability to inhibit ESBLs, AmpC betalactamases, and serine carbapenemases [60] . However, metallo-beta-lactamases (e.g., IMP, VIM, NDM) are not inhibited by avibactam [60] . Accordingly, ceftazidimeavibactam has good activity against Enterobacteriaceae and P. aeruginosa, but not Acinetobacter and Stenotrophomonas spp. A phase III non-inferiority nosocomial pneumonia trial [61] found that ceftazidime-avibactam was non-inferior to meropenem with respect to 28-day mortality [risk difference (RD) 1.5%; 95% CI − 2.4-5.3] and cure [RD 1.9%; 95% CI − 8.1-4.3] without the emergence of resistance [62] . Of concern, though, are numerous reports of resistance to this agent are already appearing [63] [64] [65] including treatment-emergent resistance [66] .
Ceftolozane-Tazobactam Whereas ceftazidime-avibactam combines an old cephalosporin with a novel beta-lactamase inhibitor, ceftolozane-tazobactam combines an old betalactamase inhibitor with a novel cephalosporin. Ceftolozane has features of ceftazidime but has a bulkier side chain, which prevents cleavage by AmpC beta-lactamases [67] , enhancing activity against P. aeruginosa. The combination also appears to have activity against non-CRE ESBL-producing Enterobacteriaceae [68, 69] . Like ceftazidime-avibactam, ceftolozane-tazobactam has little activity against A. baumannii and Stenotrophomonas spp. [60] . The ELF/ serum AUC ratio for ceftolozane was approximately 50% [70, 71•] , indicating a potential role in VAP. The efficacy of ceftolozane-tazobactam in VAP is currently being studied (NCT02070757).
Meropenem-Vaborbactam
Meropenem-vaborbactam was approved by the FDA in 2017. Vaborbactam is a boronic acid serine β-lactamase inhibitor with activity against ESBLs, AmpCs, and serine carbapenemases but not metallo-betalactamases. Meropenem-vaborbactam has broad activity against E. coli, K. pneumoniae, and Enterobacter spp., including ESBL and CRE isolates, but activity against nonfermenting Gram-negatives is similar to meropenem alone [72] . The TANGO-2 phase III clinical trial of meropenemvaborbactam for the treatment of infections of the lung, blood, urinary tract, and abdomen was stopped prematurely following enrollment of 72 patients (43 had confirmed CRE), because the interim analysis showed a statistically significant difference in clinical cure favoring meropenem-vaborbactam over best available therapy for patients with CRE [73] . Mortality rates were also lower in patients treated with meropenem-vaborbactam. Both meropenem and vaborbactam achieve ≥ 65% ELF/serum AUC ratios in healthy adults, suggestive of activity in HAP and VAP [74] . However, pharmacokinetic data from patients with VAP indicate that meropenem ELF/serum AUC ratios may be lower (median < 30%) and highly variable [75] . The efficacy of meropenem-vaborbactam in HAP and VAP is currently being studied (NCT03006679).
Ceftobiprole Ceftobiprole, a cephalosporin broadly active against Gram-positives and Gram-negatives including P. aeruginosa, is approved in several European countries but not the USA. A recent phase III trial of 781 patients found ceftobiprole to be equivalent to linezolid plus ceftazidime in the clinical cure of HAP but perhaps inferior among VAP patients [76] . Additional studies are necessary to evaluate the effectiveness of ceftobiprole in VAP.
Antibiotics in Clinical Trials
Imipenem-Cilastatin/Relebactam Relebactam is a non-β-lactam inhibitor of β-lactamases with structural similarity to avibactam. It too has good activity against ESBLs, AmpCs, and serine carbapenemases but not metallo-beta-lactamases [77, 78] . Relebactam extends imipenem's spectrum to include otherwise resistant E. coli, K. pneumoniae, and Enterobacter spp. strains. Relebactam's activity against non-fermenting Gram-n egativ e bac teria su ch a s P. aeru gino sa, A. baumannii, and S. maltophilia appears more limited [78] . Both imipenem and relebactam showed good lung penetration, suggesting potential efficacy in VAP [79] . Phase III clinical trials of imipenem-cilastatin/relebactam vs. imipenemcilastatin or piperacillin/tazobactam in HAP and VAP are underway [80, 81] .
Plazomicin Plazomicin, an aminoglycoside derivative, avoids modification and inactivation by many of the enzymes that typically cause aminoglycoside resistance [82] . Plazomicin does not inhibit bacteria that express ribosomal methyltransferases (e.g., 16s rRNA methylases) [83] . Plazomicin has good activity against MDR Enterobacteriaceae, including ESBL and serine carbapenemase producers. Against P. aeruginosa and A. baumannii, plazomicin may be more active than amikacin [84] . In a phase III trial (CARE) studying nosocomial pneumonia caused by CRE, plazomicin exhibited a mortality benefit relative to colistin when both agents were used with either meropenem or tigecycline [85] . The efficacy of plazomicin for the treatment of VAP is unknown, and the ELF/serum AUC ratio was~13% [83] . Of note, plazomicin's renal toxicity profile appeared favorable compared with colistin [86, 87] .
Eravacycline Eravacycline has structural similarity to tigecycline and also acts by binding the ribosome to inhibit protein synthesis [88] . It has broad activity against aerobic and facultative Gram-positive and Gram-negative bacteria. Eravacycline has potent activity against Enterobacteriaceae, including ESBL-, KPC-, and NDM-producing isolates [89, 90] . Compared to tigecycline, eravacycline exhibited modestly lower MICs against A. baumannii and S. maltophilia but no enhanced activity against P. aeruginosa [89, 90] . One potential advantage of eravacycline is the availability of an oral formulation. In the phase III IGNITE1 and IGNITE4 clinical trials twice daily IV eravacycline was non-inferior to ertapenem or meropenem among patients with complicated intra-abdominal infections [91, 92] . In a phase III (IGNITE2) clinical trial of hospitalized patients with complicated urinary tract infections, eravacycline was inferior to levofloxacin [93] ; however, patients receiving IV eravacycline responded better than those receiving oral eravacycline. The role of eravacycline in VAP is currently unclear.
New Tactics: Unconventional Uses of Existing Agents
Another approach to treating patients with VAP caused by MDR bacteria is to use currently approved antibiotics in new ways to enhance efficacy.
Inhaled Antibiotics Aerosolized administration of antibiotics has the theoretical advantage of achieving high local concentrations of antimicrobial agents in the lungs, perhaps even exceeding the MICs of resistant Gram-negative bacteria. A meta-analysis of a randomized controlled trial and observational studies (437 total patients) examined the use of adjunctive nebulized antibiotics in MDR VAP and showed significantly higher clinical resolution among patients receiving nebulization (OR 1.96; 95% CI 1.30-2.96) [94] . Nebulization has been used with the following Gram-negative antibiotics: gentamicin, tobramycin, amikacin, aztreonam, ceftazidime, and colistin [95] . Current guidelines recommend adjunctive inhaled antibiotics for the treatment of VAP caused by Gramnegative bacteria susceptible to only aminoglycosides or polymyxins.
Macrolides Macrolides do not exhibit in vitro activity against most Gram-negative VAP pathogens. Yet, these agents can produce potentially beneficial immunomodulatory changes in pneumonia. A multicenter, double-blinded study of 200 ICU patients with sepsis and VAP found that adjunctive clarithromycin led to earlier VAP resolution and faster mechanical ventilation weaning [96, 97] .
Prolonged Infusions of Beta-Lactams Prolonged infusion (PI) dosing of beta-lactams includes extended infusion (3-4 h; EI) and continuous infusion (24 h; CI) dosing. VAP clinical cure was greater [98, 99] , but mortality was similar with PI piperacillin-tazobactam versus standard infusion [98] [99] [100] . VAP clinical cure was also higher with PI ceftazidime (89 vs. 52%: P < 0.001) and PI meropenem (90 vs. 60%: P < 0.001) versus standard infusion [101, 102] . Randomized trials have evaluated CI vs. standard infusion [103] [104] [105] . CI-treated patients had a lower risk of mortality (RR 0.74; 95% CI 0.56- [112] . In the subset of patients with non-fermenting Gramnegatives, the risk of recurrence favored a long duration (n = 2 studies; OR = 2.18. 95% CI 1.14-4.16) [112] . A randomized, open-label, non-inferiority study (iDIAPASON) will compare 8 versus 15 days for P. aeruginosa VAP specifically [113] . The shortest effective duration of VAP treatment a l s o r e m a i n s u n c l e a r. R e c e n t ( N C T 0 0 4 1 0 5 2 7 , NCT01554657) and ongoing (NCT01994980) trials will evaluate short (i.e., 3-5 days) durations. Currently, 7-to 8-day durations are reasonable for improving patients [9] .
Novel Strategies
Perhaps predictably, the pressures on the conventional antibiotic pipeline have led to efforts to use unconventional approaches to treat MDR Gram-negatives. Here, we briefly discuss several examples.
Cefiderocol Cefiderocol is a siderophore-cephalosporin conjugate that works as a "Trojan horse." It binds iron and then uses the bacterium's iron uptake system to penetrate the outer membrane [114] . In so doing, it overcomes multiple resistance mechanisms (e.g., porin channel deletion, efflux pump overexpression) while localizing the cephalosporin within the periplasm, adjacent to PBPs. Cefiderocol has in vitro activity against many Gram-negative bacteria, including CRE, P. aeruginosa, A. baumannii, and S. maltophilia. In a study of 753 MDR clinical isolates, including carbapenemase-and ESBL-producing bacteria, cefiderocol had superior in vitro activity to meropenem, ceftazidime, and ceftazidimeavibactam and equivalent activity to colistin and tigecycline [115] . A clinical trial for the treatment of nosocomial pneumonias comparing cefiderocol to meropenem, each in combination with linezolid, is underway (NCT03032380).
Anti-Virulence Therapies Disabling a bacterium's virulence factors may prevent it from damaging tissues and make it vulnerable to clearance by the host immune system. Such approaches are not new; antibody-containing serum that bound and inactivated diphtheria toxin was used in the 1800s [116] . Advanced agents currently under development are inhibitors of type III secretion systems [117] , complex multi-protein needle-like apparatuses used by some Gram-negative bacteria to intoxicate human cells. MEDI3902 (AstraZeneca) is a chimeric bispecific monoclonal antibody that recognizes both the tip of the P. aeruginosa type III secretion needle and surface polysaccharide Psl [118] . The presence of both antigenbinding sites confers synergistic protection against P. aeruginosa in animal models [118] . A phase II clinical trial examining the efficacy of MEDI3902 in preventing P. aeruginosa pneumonia among mechanically ventilated patients is currently enrolling patients. Additional antibody therapeutics (e.g., Aerubumab, Adiris Pharmaceuticals) are in development and entering clinical trials (NCT03027609).
Quorum-Sensing Inhibition Quorum sensing (QS) is a cell density-dependent communication system that utilizes signaling molecules (auto-inducers) to regulate virulence in many bacteria. Several natural and engineered compounds block quorum-sensing by preventing the synthesis of auto-inducers or by blocking auto-inducer receptor binding [119] and have shown efficacy in mouse models [120, 121] .
Biofilm Prevention Endotracheal tube biofilms are thought to play an important role in VAP. Biofilm eradication can be difficult, in part, because biofilm-forming bacteria can persist in the presence of antibiotics and a robust immune response [122, 123] . Endotracheal tubes coated with silver may prevent or delay development of biofilms and VAP [124] .
Phage Therapy Phages (viruses that infect bacteria) specifically target an individual bacterial species or strain, do not infect human cells, and have little or no effect on normal microbial flora. However, the development of resistance, neutralizing host immune responses, and formulation and stability issues are concerns [125] . Phages are exquisitely specific, so phage cocktails are required to target multiple species or strains within a species. Such cocktails showed promise in phase I/II clinical studies against P. aeruginosa-mediated chronic otitis [126] . Recent anecdotal reports suggest efficacy in humans against MDR P. aeruginosa and A. baumannii [127, 128] .
Other Strategies Host-directed therapies [129] , microbiome alterations (e.g., probiotics) [130] , nanotechnology [131] , endolysins [132] , and bacteriocins [133] have all been investigated as novel treatments for bacterial infections.
Summary
Gram-negative bacteria appear poised to win the antibiotic resistance war. The pace of the development and spread of MDR strains has outstripped the medical community's ability to develop novel antimicrobial agents. However, the number and breadth of new and exciting approaches currently being explored is reason for hope that the balance will soon shift. The results of preclinical, clinical, and epidemiological studies over the coming years will demonstrate whether these new approaches will indeed fulfill their promise and provide clinicians with effective treatments for VAP patients.
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